| Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. | |
| | |
MedLine Citation:
|
PMID: 19779320 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: CD4 cell count and plasma viral load are well known predictors of AIDS and mortality in HIV-1-infected patients treated with combination antiretroviral therapy (cART). This study investigated, in patients treated for at least 3 years, the respective prognostic importance of values measured at cART initiation, and 6 and 36 months later, for AIDS and death. METHODS: Patients from 15 HIV cohorts included in the ART Cohort Collaboration, aged at least 16 years, antiretroviral-naive when they started cART and followed for at least 36 months after start of cART were eligible. RESULTS: Among 14 208 patients, the median CD4 cell counts at 0, 6 and 36 months were 210, 320 and 450 cells/microl, respectively, and 78% of patients achieved viral load less than 500 copies/ml at 6 months. In models adjusted for characteristics at cART initiation and for values at all time points, values at 36 months were the strongest predictors of subsequent rates of AIDS and death. Although CD4 cell count and viral load at cART initiation were no longer prognostic of AIDS or of death after 36 months, viral load at 6 months and change in CD4 cell count from 6 to 36 months were prognostic for rates of AIDS from 36 months. CONCLUSIONS: Although current values of CD4 cell count and HIV-1 RNA are the most important prognostic factors for subsequent AIDS and death rates in HIV-1-infected patients treated with cART, changes in CD4 cell count from 6 to 36 months and the value of 6-month HIV-1 RNA are also prognostic for AIDS. |
| | |
Authors:
|
; Emilie Lanoy; Margaret May; Amanda Mocroft; Andrew Phillip; Amy Justice; Geneviève Chêne; Hansjakob Furrer; Timothy Sterling; Antonella D'Arminio Monforte; Lluís Force; John Gill; Ross Harris; Robert S Hogg; Jürgen Rockstroh; Mike Saag; Pavel Khaykin; Frank de Wolf; Jonathan A C Sterne; Dominique Costagliola |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: AIDS (London, England) Volume: 23 ISSN: 1473-5571 ISO Abbreviation: AIDS Publication Date: 2009 Oct |
Date Detail:
|
Created Date: 2009-10-13 Completed Date: 2011-01-31 Revised Date: 2011-09-26 |
Medline Journal Info:
|
Nlm Unique ID: 8710219 Medline TA: AIDS Country: England |
Other Details:
|
Languages: eng Pagination: 2199-208 Citation Subset: IM; X |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Anti-HIV Agents / therapeutic use* CD4 Lymphocyte Count Disease Progression Drug Therapy, Combination Female HIV Infections / drug therapy, mortality*, virology HIV-1* Humans Male Middle Aged Prognosis RNA, Viral Risk Factors Time Factors Viral Load Young Adult |
| Grant Support | |
ID/Acronym/Agency:
|
G0700820//Medical Research Council; U10 AA013566-09/AA/NIAAA NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Anti-HIV Agents; 0/RNA, Viral |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: CYP2B6, CYP2A6 and UGT2B7 genetic polymorphisms are predictors of efavirenz mid-dose concentration i...
Next Document: Activity, pharmacokinetics and safety of lersivirine (UK-453,061), a next-generation nonnucleoside r...